Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

905 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
Silingardi V, Federico M, Cavanna L, Avanzini P, Gobbi PG, Lombardo M, Carotenuto M, Frassoldati A, Pieresca C, Vallisa D, et al. Silingardi V, et al. Among authors: lombardo m. Leuk Lymphoma. 1995 Apr;17(3-4):313-20. doi: 10.3109/10428199509056837. Leuk Lymphoma. 1995. PMID: 8580801 Clinical Trial.
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M, Morabito F, Merli F, Molica S, Cavanna L, Sacchi S, Broglia C, Angrilli F, Ilariucci F, Stelitano C, Luisi D, Bertè R, Luminari S, Federico M, Brugiatelli M; GISL. Lombardo M, et al. Leuk Lymphoma. 2002 Sep;43(9):1795-801. doi: 10.1080/1042819021000006457. Leuk Lymphoma. 2002. PMID: 12685834
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL).
Gobbi PG, Broglia C, Valentino F, Mammi C, Lombardo M, Merli F, Luminari S, Polimeno G, Riezzo A, Lambelet P, Rovati A, Corazza GR, Federico M; Gruppo Italiano Studio Linfomi. Gobbi PG, et al. Among authors: lombardo m. Ann Oncol. 2006 Apr;17(4):676-82. doi: 10.1093/annonc/mdl002. Epub 2006 Jan 30. Ann Oncol. 2006. PMID: 16446317 Free article. Clinical Trial.
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
Federico M, Luminari S, Gobbi PG, Sacchi S, Di Renzo N, Lombardo M, Merli F, Baldini L, Stelitano C, Partesotti G, Polimeno G, Montanini A, Mammi C, Brugiatelli M. Federico M, et al. Among authors: lombardo m. Eur J Haematol. 2006 Mar;76(3):217-29. doi: 10.1111/j.1600-0609.2005.00609.x. Eur J Haematol. 2006. PMID: 16451396 Clinical Trial.
Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL).
Longo G, Fiorani C, Sacchi S, Callea V, Lombardo M, Federico M, Stelitano C, Angrilli F, Vallisa D, Gobbi PG, Ilariucci F, Frassoldati A, Petrini M, Silingardi V. Longo G, et al. Among authors: lombardo m. Haematologica. 1999 May;84(5):425-30. Haematologica. 1999. PMID: 10329921 Free article. Clinical Trial.
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.
Baldini L, Brugiatelli M, Luminari S, Lombardo M, Merli F, Sacchi S, Gobbi P, Liberati M, Cavanna L, Colombi M, Stelitano C, Goldaniga M, Morabito F, Federico M, Silingardi V; Gruppo Italiano per lo Studio dei Linfomi. Baldini L, et al. Among authors: lombardo m. J Clin Oncol. 2003 Apr 15;21(8):1459-65. doi: 10.1200/JCO.2003.07.133. J Clin Oncol. 2003. PMID: 12697867 Clinical Trial.
905 results